
    
      Investigators planned to administer low (2mg) and high (6mg) dose slow-release melatonin and
      the placebo for 4 weeks and evaluate Clinical Global Impression scale, RBD questionnaire,
      PSQI, Epworth sleepiness scale, and quality of life questionnaire (SF-36v2) before and after
      the treatment along with possible side effects and drug compliance.
    
  